Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304558 | 0.94 | ALDH1A1 (0.56) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL20530525 | 0.92 | ALDH1A1 (0.58) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL20530589 | 0.92 | ALDH1A1 (0.58) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL5825166 | 0.91 | ALDH1A1 (0.53) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL9808080 | 0.89 | ALDH1A1 (0.62) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL11679951 | 0.89 | CYP2D6 (0.61) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL1592876 | 0.86 | TDP1 (0.60) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL28959994 | 0.84 | HPGD (0.45) | CYP2D6CYP2C19DRD2DRD4TDP1 | |
| SCHEMBL11097405 | 0.84 | KDM4E (0.54) | CYP2C19TDP1ALDH1A1MAPTLMNA | |
| SCHEMBL1071252 | 0.83 | CYP2C19 (0.62) | CYP2D6CYP2C19DRD2DRD4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368194-B | Method for producing (meth) acryloyl group-terminated polyisobutylene polymer | 株式会社钟化 | 2021-03-19 | — | — | CN | disclosed |
| US-10604598-B2 | Method of producing (meth)acryloyl-terminated polyisobutylene polymer | KANEKA CORPORATION (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20180362676-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | KANEKA CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388454-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | Kaneka Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| WO-2012062229-A1 | A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE | ZENTIVA, K.S. (CZ) | 2012-05-18 | — | — | WO | disclosed |
| US-8163907-B2 | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2012-04-24 | — | — | US | disclosed |
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2011-08-18 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | RYR1, CACNA1E, CACNA1C | CYP2D6 378/4885CYP2C19 1098/4885DRD2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.